Eric di Luccio is Executive Director, Chief Technology Officer, and Head of R&D and Intellectual Property at HIROTSU BIO SCIENCE, in Japan, since 2020. Before his industry career, he served as Associate Professor (2014–2020) and Assistant Professor (2010–2014) at Kyungpook National University in South Korea, focusing his research on epigenetic anticancer therapeutics, and began his research career as a post-doctoral researcher and lecturer in Molecular and Cellular Biology and Bioinformatics at the University of California, Davis (2003–2009). Holding a PhD in Neuroscience, he has led research groups across academia and industry in cancer therapeutics and cancer diagnosis for more than 15 years.
Eric di Luccio is Executive Director, Chief Technology Officer, and Head of R&D and Intellectual Property at HIROTSU BIO SCIENCE, in Japan, since 2020. Before his industry career, he served as Associate Professor (2014–2020) and Assistant Professor (2010–2014) at Kyungpook National University in South Korea, focusing his research on epigenetic anticancer therapeutics, and began his research career as a post-doctoral researcher and lecturer in Molecular and Cellular Biology and Bioinformatics at the University of California, Davis (2003–2009). Holding a PhD in Neuroscience, he has led research groups across academia and industry in cancer therapeutics and cancer diagnosis for more than 15 years.